Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089986 · ClinicalTrials.gov registry record · Phase 2
GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,415
- Enrollment target
NCT00089986: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT00089986 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,415 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (964% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00089986, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,415 participants
- Enrollment target
Study Summary
The primary objective is to estimate the size of the GR270773 treatment effect on 28-day all-cause mortality for two doses of GR270773 versus placebo in adult subjects with suspected or confirmed Gram-negative severe sepsis. GR270773 will be administered as a three-day continuous intravenous infusion.
Primary Outcome
Mortality was assessed by the number of participants who died between days 1 and 28. A summary of death details was given which included whether the participant died between days 1 and 28, whether the death was related sepsis, cause of death, the source of the information, and whether the cause of death was verified by a death record. Participants who had withdrawn from study and all study assessments and for whom survival at day 28 could not be confirmed was treated as deaths for the primary en
Interventions
- OTHER Placebo
- DRUG Intravenous GR270773- Phospholipid Emulsion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,415 participants |
| Start Date | 2004-09-01 |
| Est. Completion | 2007-04-15 |
| Phase | Phase 2 |
What the finished NCT00089986 record still lists
NCT00089986 is an interventional study that assigns participants to a tested intervention. Its 1,415 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (964% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00089986 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00089986 about?
NCT00089986 is a clinical study titled "GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults". The primary objective is to estimate the size of the GR270773 treatment effect on 28-day all-cause mortality for two doses of GR270773 versus placebo in adult subjects with suspected or confirmed Gram-negative severe sepsis. GR270773 will be administered as a three-day continuous intravenous infusio...
What is the current status of trial NCT00089986?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,415 participants. The study started on 2004-09-01. Estimated completion is 2007-04-15.
What interventions are being tested in trial NCT00089986?
The interventions under investigation include: Placebo (OTHER), Intravenous GR270773- Phospholipid Emulsion (DRUG).
Who is sponsoring clinical trial NCT00089986?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00089986's enrollment target sits among peer trials
1,415 12th of 2000 higher than 1,989 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05890404 · 1,410 participants · NA
SGM Evidenced-Based Mental Healthcare Implementation
- NCT07042451 · 1,410 participants · NA
An Evaluation of the Pink Cloud Application in Post- Treatment Substance Use Disorder Support
- NCT07222566 · 1,410 participants · Phase 3
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT05992935 · 1,405 participants · Phase 1
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI